Rivaroxaban vs. Warfarin in CVT Treatment

• Status: Completed
• Trial end date: 2020-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Cerebral venous thrombosis (CVT) is an uncommon venous-type of stroke tends to affect younger patients with somewhat different risk factors and much better outcome compared to arterial strokes. Anti-coagulation is the standard of treatment for patients with (CVT) initially with heparins followed by other oral blood thinners for several months. In this study, the investigators are comparing warfarin with another well-known blood thinner, rivaroxaban, which has a fixed once-daily dose with no need for monitoring in terms of clinical outcomes and complications.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Damascus University
• Collaborator: Unipharma, HamaPharma, Almujtahed hospital
• Treatments: Rivaroxaban; Warfarin

Criteria

Inclusion Criteria:

• patients aged 14 years or older and weighing more than 50 kg.

• Recent diagnosis of symptomatic cerebral venous thrombosis confirmed by MRI modalities, CT venography, or conventional angiography.

Exclusion Criteria:

• Any absolute contraindication to anticoagulation.

• Impaired renal function (CrCl < 30 mL/min using Cockcroft-Gault equation).

• Pregnancy or lactation at randomization.

• mandatory other blood thinners use (e.g. Aspirin).